[Control of the liberation of mediators at adrenergic nerve endings].
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001338:Autonomic Fibers, Postganglionic / Q000502:physiology; D001693:Biological Transport, Active; D002395:Catecholamines / Q000378:metabolism*; D004558:Electric Stimulation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005089:Exocytosis; D007477:Ions; D008954:Models, Biological; D009411:Nerve Endings / Q000502:physiology*; D009467:Neuromuscular Depolarizing Agents / Q000494:pharmacology; D009474:Neurons / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D009647:Normetanephrine / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000494:pharmacology; D011453:Prostaglandins / Q000494:pharmacology; D011941:Receptors, Adrenergic; D011955:Receptors, Drug; D012636:Secretory Rate / Q000187:drug effects; D013564:Sympathetic Nervous System / Q000502:physiology*; D013565:Sympatholytics / Q000494:pharmacology; D013572:Synaptic Vesicles / Q000378:metabolism; D014439:Tyramine / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D002395:Catecholamines; D004791:Enzyme Inhibitors; D007477:Ions; D009467:Neuromuscular Depolarizing Agents; D011453:Prostaglandins; D011941:Receptors, Adrenergic; D011955:Receptors, Drug; D013565:Sympatholytics; D009647:Normetanephrine; D010643:Phenoxybenzamine; D009638:Norepinephrine; D014439:Tyramine
Les contröles de la libération des médiateurs aux terminaisons des nerf adrénergiques